Ownership history in VANGUARD GROUP INC Β· 8 quarters on record
This page tracks every 13F SEC filing in which VANGUARD GROUP INC reported a position in SERINA THERAPEUTICS INC (SER). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π VANGUARD GROUP INC underperformed the S&P 500 by β90.9% annually on this SER position. Timing score: 33% (2/6 decisions correct). Average cost basis: $6.00. Maximum drawdown during holding period: β80.1%.
β Significantly underperformed the S&P 500 by 90.9% ann.
6 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 6 add/trim decisions correct
Best entry: $5.01 (2024 Q4) Β· Worst: $9.58 (2024 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 0 trims. Bought during 3 of 4 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size